BMRN BioMarin Pharmaceutical Inc. - Common Stock
NASDAQ · Biotechnology · View on SEC EDGAR ↗ 10-K/10-Q Aug 6, 2026BMRN Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
BMRN Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
About BioMarin Pharmaceutical Inc. - Common Stock Company overview from Wikipedia
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I (MPS I), by manufacturing laronidase (Aldurazyme, commercialized by Genzyme Corporation). BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials.
History
BioMarin was founded in 1997 by Christopher Starr Ph.D. and Grant W. Denison Jr. with an investment of a $1.5 million from Glyko Biomedical and went public in 1999. Seed investors were amongst others MPM Bioventures, Grosvenor Fund and Florian Schönharting.
Business development
In 2002, BioMarin acquired Glyko Biomedical. In 2009, BioMarin acquired Huxley Pharmaceuticals, Inc. (Huxley), which had rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate. In 2010, BioMarin was granted marketing approval by the European Commission for 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate for the treatment of the rare autoimmune disease Lambert–Eaton myasthenic syndrome (LEMS). BioMarin launched the product under the name Firdapse.
In 2010, BioMarin acquired LEAD Therapeutics, Inc. (LEAD), a small private drug discovery and early stage development company with key compound LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor studied for the treatment of patients with rare, genetically defined cancers. This acquisition was followed by the purchase of ZyStor Therapeutics, Inc. (ZyStor), a privately held biotechnology company developing ERTs for the treatment of lysosomal storage disorders and its lead product candidate, ZC-701, a fusion of insulin-like growth factor 2 and alpha glucosidase (IGF2-GAA) in development for Pompe disease. At its R&D day in October 2010, BioMarin also announced a new program for a peptide therapeutic, vosoritide (BMN-111), for the treatment of achondroplasia.
In 2012, BioMarin acquired Zacharon Pharmaceuticals, a private biotechnology company based in San Diego focused on developing small molecules targeting pathways of glycan metabolism. In 2014, BioMarin acquired a histone deacetylase inhibitor chemical library from Repligen for $2 million with the intention of advancing work toward therapies for Friedreich's ataxia and other neurological disorders. In November 2014, the company agreed to the acquisition of Prosensa for up to $840 million; however, the range of treatments for Duchenne muscular dystrophy failed to attain FDA approval, and development ceased in May 2016. In October 2019 it was revealed that the group will open an office in Dublin to support further growth through Europe, the Middle East and Asia. In December 2025, BioMarin agreed to acquire Amicus Therapeutics for $4.8 billion.
Acquisition history
The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):
Products
As of 2022, BioMarin has six products on the market, each of which is an orphan drug.
Tetrahydrobiopterin (branded as Kuvan) (sapropterin dihydrochloride), a small molecule drug for phenylketonuria, introduced in 2007 as the first medication-based intervention to treat phenylketonuria
Arylsulfatase B (branded as Naglazyme) (galsulfase), a recombinant protein therapeutic for Maroteaux–Lamy syndrome (also called mucopolysaccharidosis type VI)
Iduronidase (branded as Aldurazyme), a recombinant protein therapeutic for mucopolysaccharidosis I
Amifampridine (branded as Firdapse), a small molecule drug for Lambert–Eaton myasthenic syndrome (as of 2013 approved in the EU only)
Elosulfase alfa (branded as Vimizim), is the only enzyme replacement therapy to address the cause of Morquio A Syndrome (MPS IVA), which affects an estimated 3,000 patients in the developed world. The disease occurs as a result of a deficiency of activity in an enzyme involved in glycosaminoglycan (GAG) metabolism.
Cerliponase alfa (branded as Brineura), is an enzyme replacement treatment for Batten disease, which is a form of neuronal ceroid lipofuscinosis. It was approved in 2017.
Valoctocogene roxaparvovec (branded as Roctavian) is an adeno-associated viral vector for treatment of hemophilia A that aims to transfer a working copy of the Factor VIII gene into patients who lack one. It was approved in the EU in August 2022.
Biomarin is working to develop several new drugs.
Controversies
In 2010, BioMarin became involved in controversy surrounding 3,4-diaminopyridine (3,4-DAP). BioMarin markets a phosphate salt of 3,4-DAP under the name Firdapse. In 2010, BioMarin was granted exclusive licensing rights to Firdapse for 10 years. As a result, the price of a prescribed National Health Service treatment course has increased from $1,987 for the unlicensed drug to $69,970 for Firdapse. The company states that prior to its licensing, there was no guaranteed quality control of the product and no way of formally monitoring for uncommon side effects through the regulatory process.
In 2013, BioMarin Pharmaceuticals was at the center of a high-profile debate regarding expanded access of cancer patients to experimental drugs. On the advice of her doctor, Andrea Sloan, a patient with advanced ovarian cancer, requested that the company provide her with access to BMN 673, an unapproved PARP inhibitor drug candidate that had exhibited promising activity in a small Phase 1 clinical trial. The company declined, citing safety concerns. Ms. Sloan eventually received a similar drug candidate from a different company.
In 2015, there was another controversy over expanded access, concerning the supply of a drug on clinical trial to a German child who was suffering from a brain disorder but who was not part of the trial.
In April 2019, the BBC reported that patients who took part in a trial treatment for the drug Kuvan (sapropterin hydrochloride) were later denied access to it. The company was criticised by the NHS and Stephen Hammond MP for patient profiteering. The company commented the following in response: "BioMarin is disappointed that the NHS England has not recognised the value of treating PKU patients with Kuvan, despite more than a decade of positive patient outcomes across 26 countries in Europe, Russia and Turkey"
In June 2019, a Belgian court ordered BioMarin to continue supplying Vimizim to a young girl suffering from Morquio syndrome free of charge. BioMarin stopped providing free Vimizim at the beginning of the year after negotiations with Belgian health authorities regarding reimbursement of the product repeatedly failed. This caused the parents to start legal proceedings to force the company to keep providing the medicine free of charge. BioMarin was ordered in a preliminary injunction to keep doing so until a definitive judgment would be rendered, or until the medicine would be available on the Belgian market at a reasonable price.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | BMRN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 142.95Y avg ≈11.8 | ≈11.8 | 35.7 | Overvalued | |
| P/S (TTM) | 3.25Y avg ≈6.7 | ≈6.7 | 9.7 | Undervalued | |
| P/B (MRQ) | 1.75Y avg ≈3.2 | ≈3.2 | 7.2 | Undervalued | |
| Price / FCF (TTM) | 14.65Y avg ≈152.1 | ≈152.1 | · | · | |
| Price / Cash Flow (TTM) | 12.65Y avg ≈62.6 | ≈62.6 | 16.0 | Fair value | |
| Price / Tangible Book (MRQ) | 7.55Y avg ≈3.5 | ≈3.5 | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | BMRN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | 4.4%5Y avg ≈7.8% | ≈7.8% | 11.2% | In line | |
| EBITDA Margin (TTM) | 8.9%5Y avg ≈12.0% | ≈12.0% | 11.2% | In line | |
| Pretax Margin (TTM) | 4.4%5Y avg ≈9.0% | ≈9.0% | 11.6% | Below avg | |
| Net Profit Margin (TTM) | 2.1%5Y avg ≈7.2% | ≈7.2% | 4.5% | In line | |
| ROA (TTM) | 0.76%5Y avg ≈2.9% | ≈2.9% | -22.9% | Top tier | |
| ROE (TTM) | 1.2%5Y avg ≈3.7% | ≈3.7% | 5.8% | In line | |
| ROIC | 4.9%5Y avg ≈3.2% | ≈3.2% | 13.6% | Weak |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | BMRN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.7 | · | 0.7 | High debt | |
| Current Ratio (MRQ) | 2.45Y avg ≈4.4 | ≈4.4 | 3.2 | Low liquidity | |
| Quick Ratio | 2.95Y avg ≈2.1 | ≈2.1 | 1.8 | Low liquidity | |
| Long-Term Debt / Equity (MRQ) | 0.6 | · | 0.6 | In line |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | BMRN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 12.9%5Y avg ≈11.8% | ≈11.8% | · | · | |
| Revenue CAGR 3Y | 15.4%5Y avg ≈13.4% | ≈13.4% | · | · | |
| Revenue CAGR 5Y | 11.6% | · | · | · | |
| EPS YoY | -18.6%5Y avg ≈50.5% | ≈50.5% | · | · | |
| Net Income YoY | -18.3%5Y avg ≈51.6% | ≈51.6% | · | · | |
| EPS CAGR 3Y | 33.9% | · | · | · | |
| EPS CAGR 5Y | -16.7% | · | · | · | |
| Net Income CAGR 3Y | 35.1% | · | · | · | |
| Net Income CAGR 5Y | -16.4% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | BMRN | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.45Y avg ≈0.4 | ≈0.4 | 0.5 | In line | |
| Inventory Turnover | 0.65Y avg ≈0.6 | ≈0.6 | 0.8 | Weak | |
| Receivables Turnover | 4.15Y avg ≈4.5 | ≈4.5 | 4.5 | In line | |
| Revenue / Employee | ≈$1.0M | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | Aug 3, 2026 | $0.73 | $0.70 | 4.0% |
| March 31, 2026 | $0.54 | $0.77 | -29.5% | |
| Dec. 31, 2025 | $-0.24 | $0.64 | -137.7% | |
| Sept. 30, 2025 | $-0.16 | $0.38 | -142.2% | |
| June 30, 2025 | $1.23 | $0.85 | 44.4% | |
| March 31, 2025 | $0.95 | $0.72 | 31.5% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Cost of Revenue | $717M | $580M | $532M | $503M | $471M | $524M | $359M | $315M | $242M | $210M | $152M | $122M | |
| R&D Expense | $922M | $747M | $747M | $650M | $629M | $628M | $715M | $696M | $611M | $662M | $635M | $462M | |
| SG&A Expense | $1.15B | $1.01B | $892M | $823M | $759M | $738M | $681M | $604M | $554M | $477M | $402M | $302M | |
| Operating Expenses | $2.81B | $2.37B | $2.23B | $1.94B | $1.93B | $1.90B | $1.80B | $1.61B | $1.33B | $1.92B | $1.00B | $842M | |
| Operating Income | $409M | $484M | $186M | $161M | $-82M | $-43M | $-100M | $-124M | $-15M | $-803M | $-111M | $-93M | |
| Interest Expense | · | · | $17M | $16M | $15M | $29M | $23M | $44M | $43M | $39M | $38M | $37M | |
| Interest Income | $75M | $75M | $58M | $18M | $10M | $17M | $23M | $23M | $15M | $7M | $5M | $6M | |
| Pretax Income | $482M | $542M | $189M | $150M | $-75M | $-49M | $-95M | $-143M | $-36M | $-831M | $-155M | $-125M | |
| Income Tax | $134M | $115M | $21M | $8M | $-11M | $-903M | $-71M | $-65M | $81M | $-201M | $17M | $9M | |
| Net Income | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| EPS (Basic) | $1.82 | $2.25 | $0.89 | $0.76 | $-0.35 | $4.72 | $-0.13 | $-0.44 | $-0.67 | $-3.80 | $-1.07 | $-0.92 | |
| EPS (Diluted) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 | $-1.07 | $-0.92 | |
| Shares (Basic) | 191,787,000 | 190,027,000 | 187,834,000 | 185,266,000 | 182,852,000 | 180,804,000 | 179,039,000 | 177,061,000 | 174,427,000 | 165,985,000 | 160,025,000 | 146,349,000 | |
| Shares (Diluted) | 197,394,000 | 196,708,000 | 191,595,000 | 188,963,000 | 182,852,000 | 191,678,000 | 179,039,000 | 177,268,000 | 174,427,000 | 166,219,000 | 160,025,000 | 146,349,000 | |
| EBITDA | $489M | $581M | $262M | $252M | $26M | $68M | $5M | $-28M | $73M | $-707M | $-64M | $-93M |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.31B | $943M | $755M | $725M | $587M | $649M | $437M | $494M | $598M | $408M | $397M | $875M | |
| Short-term Investments | · | · | · | · | · | · | · | · | $798M | $381M | $196M | $70M | |
| Receivables | $908M | $661M | $634M | $461M | $373M | $448M | $377M | $343M | $261M | $215M | $165M | $144M | |
| Inventory | $1.30B | $1.23B | $1.11B | $894M | $777M | $699M | $680M | $531M | $476M | $355M | $272M | $199M | |
| Prepaid Expense | · | · | · | · | · | · | · | · | · | · | $28M | $35M | |
| Other Current Assets | $186M | $202M | $141M | $105M | $110M | $130M | $131M | $98M | $74M | $62M | $60M | $109M | |
| Current Assets | $3.95B | $3.23B | $2.96B | $2.75B | $2.27B | $2.34B | $1.94B | $2.06B | $2.21B | $1.42B | $1.09B | $1.40B | |
| PP&E (Net) | $953M | $1.04B | $1.07B | $1.07B | $1.04B | $1.03B | $1.01B | $949M | $897M | $799M | $704M | $524M | |
| PP&E (Gross) | $2.03B | $1.93B | $1.93B | $1.88B | $1.76B | $1.67B | $1.56B | $1.42B | $1.30B | $1.14B | $983M | $752M | |
| Accum. Depreciation | $1.07B | $892M | $867M | $802M | $721M | $636M | $549M | $473M | $407M | $343M | $279M | $229M | |
| Goodwill | $196M | $196M | $196M | $196M | $196M | $196M | $197M | $197M | $197M | $197M | $197M | $54M | |
| Intangibles | $214M | $255M | $295M | $339M | $389M | $417M | $457M | $492M | $518M | $554M | $684M | $157M | |
| Other Non-current Assets | $277M | $251M | $172M | $176M | $152M | $142M | $122M | $37M | $30M | $33M | $409M | $55M | |
| Total Assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Accounts Payable | $759M | $607M | $683M | $573M | $498M | $493M | $571M | $437M | $402M | $371M | $393M | $232M | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | · | · | $98M | |
| Current Liabilities | $759M | $607M | $1.18B | $589M | $546M | $493M | $933M | $523M | $817M | $439M | $445M | $236M | |
| Capital Leases | $37M | $31M | $38M | $26M | $32M | $40M | $44M | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | $0 | $144M | · | |
| Other Non-current Liabilities | $151M | $129M | $120M | $100M | $98M | $114M | $98M | $59M | $59M | $42M | $45M | $30M | |
| Total Liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.74B | $1.74B | $1.57B | $1.46B | $1.82B | $1.26B | $1.33B | $947M | |
| Long-term Debt | $597M | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $192.0K | $191.0K | $189.0K | $186.0K | $184.0K | $182.0K | $180.0K | $178.0K | $176.0K | $173.0K | $162.0K | $149.0K | |
| Retained Earnings | $154M | $-195M | $-622M | $-789M | $-931M | $-862M | $-1.72B | $-1.69B | $-1.64B | $-1.52B | $-1.02B | $-850M | |
| AOCI | $-13M | $62M | $-29M | $-4M | $14M | $-16M | $20M | $5M | $-23M | $13M | $21M | $27M | |
| Stockholders' Equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B | $4.10B | $3.12B | $2.97B | $2.81B | $2.77B | $2.40B | $1.53B | |
| Liabilities + Equity | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B | $4.69B | $4.43B | $4.63B | $4.02B | $3.73B | $2.48B | |
| Shares Outstanding | 192,300,101 | 190,761,000 | 188,598,000 | 186,251,000 | 183,913,000 | 181,741,000 | 179,838,000 | 178,252,954 | 175,843,749 | 172,647,588 | 161,526,044 | 149,093,647 |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $80M | $96M | $104M | $102M | $108M | $105M | $105M | $96M | $88M | $97M | $47M | $46M | |
| Stock-based Comp | $181M | $202M | $207M | $196M | $197M | $190M | $160M | $149M | $140M | $135M | $112M | $86M | |
| Deferred Tax | $49M | $56M | $-45M | $-52M | $-16M | $-890M | $-83M | $-68M | $44M | $-228M | $-77M | $-26M | |
| Amort. of Intangibles | $19M | $43M | $62M | $67M | · | · | · | · | · | · | · | $10M | |
| Other Non-cash | $169M | $-208M | $-275M | $-212M | $79M | $-180M | $-110M | $-79M | $-164M | $399M | $-132M | · | |
| Operating Cash Flow | $828M | $573M | $159M | $176M | $305M | $85M | $48M | $20M | $-9M | $-228M | $-219M | $-70M | |
| CapEx | $103M | $85M | $97M | $121M | $96M | $114M | $145M | $145M | $199M | $148M | $228M | $117M | |
| Investing Cash Flow | $-414M | $136M | $-111M | $-20M | $-366M | $-54M | $-31M | $264M | $-305M | $-484M | · | · | |
| Stock Issued | · | · | · | · | · | · | · | $0 | $0 | $713M | $888M | $117M | |
| Stock Repurchased | · | · | · | $0 | $0 | $50M | $0 | $0 | · | · | · | · | |
| Net Stock Activity | · | · | · | $0 | $0 | $-50M | · | $0 | $0 | $713M | $888M | $117M | |
| Financing Cash Flow | $-42M | $-526M | $-19M | $-19M | $-48.0K | $181M | $-75M | $-388M | $507M | $727M | · | · | |
| Net Change in Cash | $369M | $188M | $31M | $137M | $-62M | $212M | $-57M | $-104M | $190M | $11M | $-478M | $307M | |
| Taxes Paid | $96M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $725M | $487M | $63M | $55M | $209M | $-29M | $-97M | $-124M | $-208M | $-376M | $-449M | $-192M | |
| Levered FCF | · | · | $47M | $40M | $196M | $566M | $-103M | $-148M | $-347M | $-406M | $-492M | $-232M |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% | -2.0% | -5.9% | -8.3% | -1.1% | -71.9% | -12.4% | -12.4% | |
| Net Margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 46.2% | -1.4% | -5.2% | -8.9% | -56.4% | -19.3% | -17.8% | |
| Pretax Margin | 15.0% | 19.0% | 7.8% | 7.1% | -4.1% | -2.3% | -5.6% | -9.6% | -2.7% | -74.4% | -17.4% | -16.6% | |
| EBITDA Margin | 15.2% | 20.3% | 10.8% | 12.0% | 1.4% | 3.7% | 0.28% | -1.9% | 5.6% | -63.3% | -7.1% | -12.4% | |
| ROA | 4.8% | 6.2% | 2.5% | 2.3% | -1.1% | 16.3% | -0.52% | -1.7% | -2.7% | -16.3% | -5.5% | -5.7% | |
| ROE | 5.8% | 7.7% | 3.4% | 3.1% | -1.5% | 21.1% | -0.77% | -2.6% | -4.2% | -24.4% | -8.8% | -9.3% | |
| ROIC | 4.9% | 6.7% | 2.8% | 3.1% | -1.6% | 18.2% | -0.81% | -2.2% | -1.7% | -22.0% | -5.1% | -6.5% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 | 4.8 | 2.1 | 3.9 | 2.7 | 3.2 | 2.4 | 6.0 | |
| Quick Ratio | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 | 2.2 | 0.9 | 1.6 | 2.0 | 2.3 | 1.7 | 4.6 | |
| Interest Coverage | · | · | 9.1 | 9.4 | -5.4 | -1.3 | -4.3 | -2.8 | -0.3 | -20.3 | -2.9 | -2.5 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
| Inventory Turnover | 0.6 | 0.5 | 0.5 | 0.6 | 0.6 | 0.8 | 0.6 | 0.6 | 0.6 | 0.7 | 0.6 | 0.7 | |
| Receivables Turnover | 4.1 | 4.4 | 4.4 | 5.0 | 4.5 | 4.5 | 4.7 | 4.9 | 5.5 | 5.9 | 5.8 | 5.7 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $31.65 | $29.66 | $26.25 | $24.71 | $23.22 | $22.59 | $17.36 | $16.65 | $15.97 | $16.02 | $14.86 | $10.25 | |
| Revenue / Share | $16.32 | $14.51 | $12.63 | $11.09 | $10.10 | $9.71 | $9.52 | $8.41 | $7.53 | $6.72 | · | · | |
| Cash Flow / Share | $4.19 | $2.91 | $0.83 | $0.93 | $1.67 | $0.45 | $0.27 | $0.11 | $-0.05 | $-1.37 | · | · | |
| Cash / Share | $6.82 | $4.94 | $4.00 | $3.89 | $3.19 | $3.57 | $2.43 | $2.77 | $3.40 | $2.37 | $2.46 | $5.87 | |
| EPS (TTM) | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 | $4.50 | $-0.13 | $-0.44 | $-0.67 | $-3.81 | $-1.07 | $-0.92 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 12.9% | 18.0% | 15.4% | 13.5% | -0.76% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 15.4% | 15.6% | 9.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 11.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -18.6% | 154.0% | 16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 33.9% | · | -42.2% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -16.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -18.3% | 154.6% | 18.4% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 35.1% | · | -41.9% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -16.4% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $890M | $749M | |
| Net Income TTM | $349M | $427M | $168M | $142M | $-64M | $854M | $-24M | $-77M | $-117M | $-630M | $-172M | $-134M | |
| Market Cap | $11.43B | $12.54B | $18.18B | $19.28B | $16.25B | $15.94B | $15.21B | $15.18B | $15.68B | $14.30B | $16.92B | $13.48B | |
| P/E | 33.0 | 29.7 | 110.8 | 138.0 | -252.4 | 19.5 | -650.4 | -193.5 | -133.1 | -21.7 | -97.9 | -98.3 | |
| P/S | 3.5 | 4.4 | 7.5 | 9.2 | 8.8 | 8.6 | 8.9 | 10.2 | 11.9 | 12.8 | 19.0 | 18.0 | |
| P/B | 1.9 | 2.2 | 3.7 | 4.2 | 3.8 | 3.9 | 4.9 | 5.1 | 5.6 | 5.2 | 7.0 | 8.8 | |
| P / Tangible Book | 2.0 | 2.4 | 4.1 | 4.7 | 4.4 | 4.6 | · | · | · | · | · | · | |
| P / Cash Flow | 13.8 | 21.9 | 114.2 | 109.6 | 53.4 | 186.7 | 315.1 | 751.1 | -1790.6 | -62.8 | -76.3 | -183.3 | |
| P / FCF | 15.8 | 25.7 | 290.6 | 350.8 | 77.8 | -550.6 | -157.1 | -122.0 | -75.4 | -38.0 | -37.7 | -70.1 | |
| Earnings Yield | 3.0% | 3.4% | 0.90% | 0.72% | -0.40% | 5.1% | -0.15% | -0.52% | -0.75% | -4.6% | -1.0% | -1.0% |
Income Statement
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $990M | $766M | $875M | $776M | $825M | $745M | $747M | $746M | $712M | $649M | $646M | $581M | $595M | $596M | $538M | $505M | |
| Cost of Revenue | $203M | $195M | $276M | $140M | $150M | $152M | $136M | $188M | $130M | $125M | $138M | $128M | $131M | $135M | $147M | $116M | |
| R&D Expense | $207M | $179M | $192M | $409M | $161M | $159M | $174M | $185M | $184M | $205M | $206M | $191M | $177M | $172M | $173M | $158M | |
| SG&A Expense | $396M | $258M | $446M | $268M | $232M | $206M | $267M | $253M | $263M | $226M | $260M | $216M | $206M | $211M | $215M | $217M | |
| Operating Expenses | $879M | $637M | $919M | $823M | $549M | $521M | $586M | $632M | $592M | $560M | $619M | $551M | $530M | $534M | $551M | $508M | |
| Operating Income | $111M | $130M | $-45M | $-47M | $277M | $224M | $161M | $114M | $120M | $88M | $27M | $31M | $66M | $62M | $-13M | $-2M | |
| Interest Expense | $61M | $10M | · | · | $2M | $2M | · | · | · | $4M | · | $4M | $4M | $4M | · | $5M | |
| Interest Income | $10M | $23M | $19M | $18M | $19M | $19M | $18M | $18M | $20M | $19M | $18M | $16M | $13M | $12M | $9M | $5M | |
| Pretax Income | $61M | $141M | $-27M | $-26M | $298M | $238M | $170M | $134M | $132M | $106M | $19M | $42M | $71M | $57M | $-18M | $-2M | |
| Income Tax | $17M | $36M | $19M | $4M | $57M | $52M | $45M | $28M | $25M | $17M | $-1M | $1M | $15M | $6M | $-17M | $5M | |
| Net Income | $45M | $106M | $-47M | $-31M | $241M | $186M | $125M | $106M | $107M | $89M | $20M | $40M | $56M | $51M | $-249.0K | $-7M | |
| EPS (Basic) | $0.23 | $0.55 | $-0.24 | $-0.16 | $1.25 | $0.97 | $0.66 | $0.56 | $0.56 | $0.47 | $0.11 | $0.21 | $0.30 | $0.27 | $-0.01 | $-0.04 | |
| EPS (Diluted) | $0.23 | $0.54 | $-0.22 | $-0.16 | $1.23 | $0.95 | $0.65 | $0.55 | $0.55 | $0.46 | $0.10 | $0.21 | $0.29 | $0.27 | $0.01 | $-0.04 | |
| Shares (Basic) | 193,423,000 | 192,497,000 | · | 192,032,000 | 191,907,000 | 190,967,000 | · | 190,429,000 | 190,114,000 | 188,866,000 | · | 188,219,000 | 187,948,000 | 186,667,000 | · | 185,597,000 | |
| Shares (Diluted) | 194,467,000 | 197,671,000 | · | 192,032,000 | 197,091,000 | 196,474,000 | · | 197,147,000 | 200,505,000 | 199,262,000 | · | 191,173,000 | 194,998,000 | 194,363,000 | · | 185,597,000 | |
| EBITDA | $111M | $146M | · | $-47M | $277M | $246M | · | $114M | $120M | $116M | · | $26M | $59M | $86M | · | $-2M |
Balance Sheet
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $874M | $2.22B | $1.31B | $1.25B | $1.21B | $1.05B | $943M | $675M | $972M | $747M | · | $785M | $694M | $580M | · | $762M | |
| Receivables | $1.06B | $904M | $908M | $790M | $856M | $739M | $661M | $778M | $691M | $637M | · | $572M | $610M | $598M | · | $420M | |
| Inventory | $1.78B | $1.27B | $1.30B | $1.38B | $1.34B | $1.27B | $1.23B | $1.18B | $1.18B | $1.14B | · | $1.03B | $976M | $919M | · | $839M | |
| Other Current Assets | $254M | $206M | $186M | $204M | $177M | $182M | $202M | $169M | $160M | $163M | · | $225M | $193M | $173M | · | $150M | |
| Current Assets | $3.97B | $4.61B | $3.95B | $3.85B | $3.81B | $3.47B | $3.23B | $3.06B | $3.26B | $2.99B | · | $2.96B | $2.95B | $2.84B | · | $2.68B | |
| PP&E (Net) | $990M | $958M | $953M | $1.04B | $1.03B | $1.03B | $1.04B | $1.05B | $1.05B | $1.06B | · | $1.07B | $1.07B | $1.07B | · | $1.05B | |
| PP&E (Gross) | $2.10B | $2.05B | $2.03B | $1.99B | $1.96B | $1.94B | $1.93B | $1.91B | $1.96B | $1.95B | · | $1.92B | $1.90B | $1.88B | · | $1.83B | |
| Accum. Depreciation | $1.11B | $1.09B | $1.07B | $950M | $931M | $908M | $892M | $869M | $910M | $888M | · | $851M | $829M | $807M | · | $782M | |
| Goodwill | $656M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | $196M | · | $196M | $196M | $196M | · | $196M | |
| Intangibles | $4.88B | $205M | $214M | $233M | $240M | $247M | $255M | $261M | $266M | $280M | · | $302M | $310M | $326M | · | $354M | |
| Other Non-current Assets | $338M | $276M | $277M | $271M | $249M | $236M | $251M | $199M | $191M | $185M | · | $165M | $144M | $150M | · | $152M | |
| Total Assets | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Accounts Payable | $1.01B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $572M | $594M | · | $670M | $597M | $598M | · | $493M | |
| Current Liabilities | $1.66B | $793M | $759M | $798M | $684M | $628M | $607M | $716M | $1.07B | $1.09B | · | $1.16B | $597M | $598M | · | $521M | |
| Capital Leases | · | · | $37M | · | · | · | $31M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $210M | $155M | $151M | $163M | $149M | $130M | $129M | $128M | $119M | $117M | · | $105M | $98M | $92M | · | $92M | |
| Total Liabilities | $5.40B | $2.38B | $1.51B | $1.56B | $1.43B | $1.35B | $1.33B | $1.44B | $1.78B | $1.80B | · | $1.86B | $1.78B | $1.77B | · | $1.70B | |
| Long-term Debt | $4.19B | $1.43B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Total Debt | $4.19B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Common Stock | $194.0K | $193.0K | $192.0K | $192.0K | $192.0K | $192.0K | $191.0K | $191.0K | $190.0K | $190.0K | · | $188.0K | $188.0K | $188.0K | · | $186.0K | |
| Retained Earnings | $304M | $260M | $154M | $201M | $232M | $-9M | $-195M | $-320M | $-426M | $-533M | · | $-642M | $-682M | $-738M | · | $-789M | |
| AOCI | $-9M | $-4M | $-13M | $-34M | $-45M | $19M | $62M | $5M | $27M | $-1M | · | $6M | $-19M | $-11M | · | $31M | |
| Stockholders' Equity | $6.32B | $6.21B | $6.09B | $6.06B | $6.03B | $5.79B | $5.66B | $5.41B | $5.29B | $5.07B | $4.95B | $4.90B | $4.78B | $4.66B | $4.60B | $4.57B | |
| Liabilities + Equity | $11.72B | $8.59B | $7.59B | $7.61B | $7.46B | $7.15B | $6.99B | $6.85B | $7.07B | $6.87B | · | $6.76B | $6.56B | $6.43B | · | $6.26B | |
| Shares Outstanding | 193,535,556 | 193,268,870 | 192,300,101 | 192,098,751 | 192,001,650 | 191,755,802 | 190,761,349 | 190,553,918 | 190,355,517 | 189,776,577 | 188,598,000 | 188,339,482 | 188,151,695 | 187,601,106 | 186,251,000 | 185,824,253 |
Cash Flow
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $98M | $16M | $20M | $18M | $19M | $22M | $24M | $19M | $26M | $27M | $27M | $26M | $25M | $26M | $25M | $25M | |
| Stock-based Comp | $76M | $43M | $47M | $49M | $48M | $38M | $52M | $43M | $48M | $58M | $55M | $48M | $50M | $54M | $47M | $55M | |
| Deferred Tax | $-7M | $9M | $613.0K | $-14M | $33M | $28M | $42M | $12M | $1M | $285.0K | $-25M | $-15M | $1M | $-6M | $-51M | $-4M | |
| Amort. of Intangibles | $73M | $4M | $5M | $5M | $5M | $5M | $10M | $5M | $14M | $14M | $15M | $16M | $16M | $16M | · | · | |
| Restructuring | $56M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $46M | · | · | · | $-99M | · | · | · | $-128M | · | · | · | $-199M | · | · | |
| Operating Cash Flow | $168M | $221M | $100M | $369M | $185M | $174M | $186M | $221M | $119M | $47M | $27M | $136M | $70M | $-74M | $7M | $158M | |
| CapEx | $29M | $21M | $41M | $28M | $17M | $17M | $20M | $18M | $21M | $26M | $29M | $22M | $22M | $24M | $36M | $29M | |
| Investing Cash Flow | $-5.10B | $726M | $-42M | $-331M | $-13M | $-28M | $76M | $-16M | $90M | $-14M | $-65M | $-46M | $30M | $-30M | $-55M | $-23M | |
| Financing Cash Flow | $2.74B | $813M | $3M | $-2M | $-5M | $-39M | $3M | $-499M | $13M | $-43M | $11M | $-788.0K | $12M | $-41M | $11M | $8M | |
| Net Change in Cash | $-2.20B | $1.76B | $62M | $36M | $165M | $106M | $267M | $-297M | $225M | $-8M | $-30M | $91M | $114M | $-144M | $-37M | $142M | |
| Free Cash Flow | · | $200M | · | · | · | $158M | · | · | · | $21M | · | · | · | $-98M | · | · | |
| Levered FCF | · | $193M | · | · | · | · | · | · | · | $18M | · | · | · | $-102M | · | · |
Profitability
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.2% | 16.9% | · | -6.0% | 33.6% | 30.0% | · | 15.3% | 16.9% | 13.6% | · | 4.4% | 9.9% | 10.0% | · | -0.48% | |
| Net Margin | 4.5% | 13.8% | · | -4.0% | 29.1% | 24.9% | · | 14.2% | 15.0% | 13.7% | · | 7.0% | 9.4% | 8.5% | · | -1.3% | |
| Pretax Margin | 6.2% | 18.4% | · | -3.4% | 36.1% | 31.9% | · | 18.0% | 18.6% | 16.3% | · | 7.2% | 11.9% | 9.5% | · | -0.38% | |
| EBITDA Margin | 11.2% | 19.1% | · | -6.0% | 33.6% | 33.0% | · | 15.3% | 16.9% | 17.8% | · | 4.4% | 9.9% | 14.4% | · | -0.48% | |
| ROA | 0.47% | 1.3% | · | -0.43% | 3.3% | 2.6% | · | 1.6% | 1.6% | 1.3% | · | 0.62% | 0.88% | 0.81% | · | -0.11% | |
| ROE | 0.72% | 1.8% | · | -0.54% | 4.2% | 3.4% | · | 2.1% | 2.1% | 1.8% | · | 0.85% | 1.2% | 1.1% | · | -0.15% | |
| ROIC | 0.77% | 1.6% | · | -0.90% | 3.7% | 3.0% | · | 1.7% | 1.8% | 1.5% | · | 0.51% | 0.97% | 1.1% | · | -0.18% |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.4 | 5.8 | · | 4.8 | 5.6 | 5.5 | · | 4.3 | 3.1 | 2.7 | · | 2.5 | 4.9 | 4.8 | · | 5.1 | |
| Quick Ratio | 1.2 | 3.9 | · | 2.6 | 3.0 | 2.8 | · | 2.0 | 1.6 | 1.3 | · | 1.2 | 2.2 | 2.0 | · | 2.3 | |
| Debt / Equity | 0.7 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| LT Debt / Equity | 0.6 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Interest Coverage | 1.8 | 13.5 | · | · | · | · | · | · | · | 24.9 | · | 6.8 | 15.7 | 16.0 | · | -0.5 |
Efficiency
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.1 | 0.2 | · | 0.1 | 0.1 | 0.1 | · | 0.2 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.0 | 0.9 | · | 1.0 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.2 | 1.1 | 1.2 | · | 1.3 |
Per Share
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $32.66 | $32.14 | · | $31.53 | $31.39 | $30.21 | · | $28.41 | $27.77 | $26.74 | · | $26.00 | $25.42 | $24.83 | · | $24.59 | |
| Revenue / Share | $5.09 | $3.88 | · | $4.04 | $4.19 | $3.79 | · | $3.78 | $3.55 | $3.26 | · | $3.04 | $3.05 | $3.07 | · | $2.72 | |
| Cash Flow / Share | · | $1.12 | · | · | · | $0.89 | · | · | · | $0.24 | · | · | · | $-0.38 | · | · | |
| Cash / Share | $4.52 | $11.50 | · | $6.51 | $6.32 | $5.47 | · | $3.54 | $5.11 | $3.94 | · | $4.17 | $3.69 | $3.09 | · | $4.10 | |
| EPS (TTM) | $0.39 | $1.39 | · | $2.67 | $3.38 | $2.70 | · | $1.66 | $1.32 | $1.06 | · | $0.78 | $0.53 | $0.39 | · | $0.43 |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.41B | $3.24B | · | $3.09B | $3.06B | $2.95B | · | $2.75B | $2.59B | $2.47B | · | $2.31B | $2.23B | $2.17B | · | $2.01B | |
| Net Income TTM | $73M | $269M | · | $520M | $657M | $524M | · | $322M | $257M | $205M | · | $147M | $100M | $72M | · | $84M | |
| Market Cap | $11.07B | $10.92B | · | $10.40B | $10.55B | $13.56B | · | $13.39B | $15.67B | $16.58B | · | $16.66B | $16.31B | $18.24B | · | $15.75B | |
| Enterprise Value | $14.39B | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | 146.7 | 40.6 | · | 20.3 | 16.3 | 26.2 | · | 42.3 | 62.4 | 82.4 | · | 113.4 | 163.5 | 249.3 | · | 197.1 | |
| P/S | 3.3 | 3.4 | · | 3.4 | 3.4 | 4.6 | · | 4.9 | 6.1 | 6.7 | · | 7.2 | 7.3 | 8.4 | · | 7.8 | |
| P/B | 1.8 | 1.8 | · | 1.7 | 1.8 | 2.3 | · | 2.5 | 3.0 | 3.3 | · | 3.4 | 3.4 | 3.9 | · | 3.4 | |
| P / Tangible Book | 14.1 | 1.9 | · | 1.8 | 1.9 | 2.5 | · | 2.7 | 3.2 | 3.6 | · | 3.8 | 3.8 | 4.4 | · | 3.9 | |
| P / Cash Flow | · | 49.5 | · | · | · | 77.7 | · | · | · | 352.9 | · | · | · | -246.7 | · | · | |
| EV / Revenue | 4.2 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | 0.68% | 2.5% | · | 4.9% | 6.2% | 3.8% | · | 2.4% | 1.6% | 1.2% | · | 0.88% | 0.61% | 0.40% | · | 0.51% |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B |
| Operating Margin % | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% |
| Net Income | $349M | $427M | $168M | $142M | $-64M |
| Diluted EPS | $1.80 | $2.21 | $0.87 | $0.75 | $-0.35 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Current Ratio | 5.2 | 5.3 | 2.5 | 4.7 | 4.2 |
| Quick Ratio | 2.9 | 2.6 | 1.2 | 2.0 | 1.8 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $725M | $487M | $63M | $55M | $209M |
Institutional owners (13F) 616 filers · $12.2B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 89 (-16 vs prior Q) | 75 (+9 vs prior Q) | 209 (+1 vs prior Q) | 199 (+30 vs prior Q) | +10.2M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| BlackRock, Inc. | $1,169,875,004 | 20,445,212 | 9.56% | Shares |
| VANGUARD GROUP INC | $1,077,337,946 | 18,127,847 | 8.81% | Shares |
| Dodge & Cox | $849,426,895 | 14,844,930 | 6.94% | Shares |
| PRIMECAP MANAGEMENT CO/CA/ | $811,962,329 | 14,190,183 | 6.64% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $500,310,680 | 8,743,633 | 4.09% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $494,877,355 | 8,648,678 | 4.05% | Shares |
| NORGES BANK | $469,659,128 | 8,207,954 | 3.84% | Shares |
| STATE STREET CORP | $446,370,874 | 7,800,959 | 3.65% | Shares |
| VIKING GLOBAL INVESTORS LP | $435,819,735 | 7,616,563 | 3.56% | Shares |
| Vestal Point Capital, LP | $344,750,500 | 6,025,000 | 2.82% | Shares |
| AQR CAPITAL MANAGEMENT LLC | $322,537,038 | 5,699,541 | 2.64% | Shares |
| FMR LLC | $275,965,970 | 4,822,893 | 2.26% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $233,217,034 | 4,075,714 | 1.91% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $223,885,722 | 3,911,794 | 1.83% | Shares |
| Capital Research Global Investors | $200,521,024 | 3,504,387 | 1.64% | Shares |
| Deep Track Capital, LP | $189,254,063 | 3,307,481 | 1.55% | Shares |
| MILLENNIUM MANAGEMENT LLC | $118,549,312 | 2,071,816 | 0.97% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $92,468,664 | 1,616,020 | 0.76% | Shares |
| FIRST TRUST ADVISORS LP | $91,910,897 | 1,606,273 | 0.75% | Shares |
| NORTHERN TRUST CORP | $89,154,711 | 1,558,104 | 0.73% | Shares |
| MORGAN STANLEY | $86,115,553 | 1,504,989 | 0.70% | Shares |
| Jones Hill Capital LP | $81,915,580 | 1,431,590 | 0.67% | Shares |
| Assenagon Asset Management S.A. | $80,373,600 | 1,339,560 | 0.66% | Shares |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $76,264,876 | 1,332,836 | 0.62% | Shares |
| Swedbank AB | $75,232,112 | 1,314,787 | 0.61% | Shares |
| UBS Group AG | $73,613,817 | 1,286,505 | 0.60% | Shares |
| DNB Asset Management AS | $72,566,061 | 1,268,194 | 0.59% | Shares |
| Caisse de depot et placement du Quebec | $70,749,440 | 1,236,446 | 0.58% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $70,030,356 | 1,223,879 | 0.57% | Shares |
| GOLDMAN SACHS GROUP INC | $68,777,119 | 1,201,977 | 0.56% | Shares |
| AMERIPRISE FINANCIAL INC | $66,255,506 | 1,157,865 | 0.54% | Shares |
| Bank of New York Mellon Corp | $66,106,543 | 1,155,305 | 0.54% | Shares |
| CITADEL ADVISORS LLC | $64,224,186 | 1,122,408 | 0.52% | Shares |
| Balyasny Asset Management L.P. | $60,344,956 | 1,054,613 | 0.49% | Shares |
| ARGA Investment Management, LP | $59,474,983 | 1,039,409 | 0.49% | Shares |
| Brandywine Global Investment Management, LLC | $56,211,687 | 945,847 | 0.46% | Shares |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $54,484,884 | 952,200 | 0.45% | Call option |
| FRANKLIN RESOURCES INC | $53,560,439 | 936,044 | 0.44% | Shares |
| MACKENZIE FINANCIAL CORP | $53,321,258 | 931,864 | 0.44% | Shares |
| JANUS HENDERSON GROUP PLC | $48,409,915 | 857,010 | 0.40% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $48,062,765 | 850,819 | 0.39% | Shares |
| Hudson Bay Capital Management LP | $47,206,614 | 825,002 | 0.39% | Shares |
| Russell Investments Group, Ltd. | $44,813,913 | 783,148 | 0.37% | Shares |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $42,723,120 | 712,052 | 0.35% | Shares |
| LOOMIS SAYLES & CO L P | $40,835,454 | 713,657 | 0.33% | Shares |
| JPMORGAN CHASE & CO | $40,573,267 | 694,550 | 0.33% | Shares |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $39,869,980 | 696,784 | 0.33% | Shares |
| Nuveen, LLC | $39,432,077 | 689,131 | 0.32% | Shares |
| EDMOND DE ROTHSCHILD HOLDING S.A. | $39,311,857 | 687,030 | 0.32% | Shares |
| Palo Alto Investors LP | $39,068,500 | 682,777 | 0.32% | Shares |
Activists & 5%+ owners 4 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| BioMarin Pharmaceutical Inc., BioMarin Falcons B.V., BioMarin Giants B.V. ×5 filings | Feb. 2, 2015 | · | Initial filing | · | SEC |
| Millenco LLC, Integrated Core Strategies (US) LLC, Catapult Partners, Ltd., Catapult Capital Management LLC, Millennium International Management LP, Millennium International Management GP LLC, Millennium Management LLC, Israel A. Englander ×2 filings | July 31, 2009 | · | Initial filing | · | SEC |
| June 6, 2005 | · | Initial filing | Board campaign | SEC | |
| OrbiMed Advisors LLC, OrbiMed Capital LLC, Samuel D. Isaly, Richard B. Brewer, Joseph Klein, III ×2 filings | May 6, 2005 | · | Initial filing | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 50 insiders · 21 officers · 30 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Alexander Hardy | Chief Executive Officer | March 17, 2026 F | 214,635 | 0 | 0 | $0 |
| Louis Drapeau | Chief Executive Officer | May 2, 2005 A | 14,934 | 0 | 0 | $0 |
| Fredric D Price | Chief Executive Officer | May 6, 2004 P | 79,285 | 0 | 0 | $0 |
| Brian Mueller | EVP, Chief Financial Officer | March 17, 2026 F | 123,314 | 0 | 0 | $0 |
| Daniel K Spiegelman | EVP, Chief Financial Officer | April 30, 2019 A | 47,686 | 0 | 0 | $0 |
| Jeffrey H Cooper | SVP, Chief Financial Officer | May 14, 2012 M | 41,089 | 0 | 0 | $0 |
| Henry J Fuchs | President, Worldwide R&D | Sept. 13, 2024 F | 185,074 | 0 | 0 | $0 |
| Robert Baffi | President, Global Mfg/Tech Ops | March 20, 2020 F | 117,138 | 0 | 0 | $0 |
| Gregory R Friberg | EVP, Chief R&D Officer | Sept. 30, 2026 F | 47,732 | 0 | 2 | $-558,646 |
| George Eric Davis | EVP, Chief Legal Officer | Sept. 2, 2026 S | 61,003 | 0 | 2 | $-2,762,781 |
| Cristin Hubbard | EVP, Chief Commercial Officer | May 20, 2026 F | 42,472 | 0 | 0 | $0 |
| Charles Greg Guyer | EVP, Chief Technical Officer | March 17, 2026 F | 84,140 | 0 | 1 | $-996,744 |
| Rashmi Virendra Ramchandani | VP, Chief Accounting Officer | Jan. 20, 2026 A | 25,610 | 0 | 0 | $0 |
| Erin Burkhart | GVP, Chief Accounting Officer | May 20, 2025 S | 14,173 | 0 | 0 | $0 |
| Jeffrey Robert Ajer | EVP, Chief Commercial Officer | May 2, 2024 S | 66,767 | 0 | 0 | $0 |
| Andrea Acosta | GVP, Chief Accounting Officer | July 16, 2021 F | 18,122 | 0 | 0 | $0 |
| Steve Aselage | EVP, Chief Business Officer | July 2, 2012 M | 59,030 | 0 | 0 | $0 |
| Emil D Kakkis | Chief Medical Officer | March 2, 2009 M | 39,621 | 0 | 0 | $0 |
| Stuart J Swiedler | SVP, Clinical Affairs | July 7, 2008 A | 12,000 | 0 | 0 | $0 |
| Christopher M Starr | SVP, Chief Scientific Officer | Dec. 1, 2005 M | 295,176 | 0 | 0 | $0 |
| Jeffrey Landau | SVP, Administration | Oct. 31, 2004 A | 2,740 | 0 | 0 | $0 |
| Robert M Plenge | Director | Sept. 10, 2026 A | 6,140 | 0 | 0 | $0 |
| Elizabeth M Anderson | Director | June 2, 2026 A | 41,940 | 0 | 0 | $0 |
| Barbara W. Bodem | Director | June 2, 2026 A | 21,045 | 0 | 0 | $0 |
| Maykin Ho | Director | June 2, 2026 A | 35,500 | 0 | 0 | $0 |
| Mark J Enyedy | Director | June 2, 2026 A | 21,040 | 0 | 0 | $0 |
| Athena Countouriotis | Director | June 2, 2026 A | 21,040 | 0 | 0 | $0 |
| Robert J. Hombach | Director | June 2, 2026 A | 49,360 | 0 | 0 | $0 |
| Timothy P Walbert | Director | June 2, 2026 A | 17,270 | 0 | 0 | $0 |
| Ian T Clark | Director | June 2, 2026 A | 14,490 | 0 | 0 | $0 |
| Willard H Dere | Director | June 2, 2026 A | 46,440 | 0 | 0 | $0 |
| Richard A Meier | Director | May 20, 2025 A | 127,426 | 0 | 0 | $0 |
| Elaine J Heron | Director | June 3, 2024 M | 97,720 | 0 | 0 | $0 |
| David E I Pyott | Director | May 21, 2024 A | 49,750 | 0 | 0 | $0 |
| Jean Jacques Bienaime | Director | May 20, 2024 F | 473,792 | 0 | 0 | $0 |
| Dennis Slamon | Director | March 18, 2024 M | 31,299 | 0 | 0 | $0 |
| Mark J Alles | Director | May 23, 2023 A | 15,095 | 0 | 0 | $0 |
| Bryan V Lawlis | Director | May 23, 2023 A | 33,140 | 0 | 0 | $0 |
| Michael G Grey | Director | March 5, 2021 M | 42,840 | 0 | 0 | $0 |
| Alan Lewis | Director | June 4, 2019 A | 25,590 | 0 | 0 | $0 |
| Kathryn E Falberg | Director | July 15, 2016 A | 2,640 | 0 | 0 | $0 |
| William D Young | Director | June 10, 2015 A | 11,875 | 0 | 0 | $0 |
| Kenneth Bate | Director | June 10, 2015 A | 11,875 | 0 | 0 | $0 |
| Pierre Lapalme | Director | June 10, 2015 A | 31,250 | 0 | 0 | $0 |
| Joseph Klein III | Director | March 8, 2010 S | 35,000 | 0 | 0 | $0 |
| Franz L Cristiani | Director | June 14, 2006 A | · | 0 | 0 | $0 |
| Erich Sager | Director | Feb. 24, 2006 M | 3,309 | 0 | 0 | $0 |
| Gwynn Williams | Director | Nov. 30, 2004 A | 812,565 | 0 | 0 | $0 |
| John Urquhart | Director | July 28, 2004 A | · | 0 | 0 | $0 |
| Mark Wood | · | May 22, 2013 M | 20,277 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 85 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2.32% | 176,657 SH | Oct. 23, 2026 | Daily |
| BBP · ETFis Series Trust I | 1.48% | 24,255 NS | July 31, 2026 | N-PORT |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.31% | 15,080 NS | July 31, 2026 | N-PORT |
| SRHQ · Elevation Series Trust | 1.17% | 41,384 NS | July 31, 2026 | N-PORT |
| RNIN · EA Series Trust | 1.15% | 35,050 NS | July 31, 2026 | N-PORT |
| IBB · iShares Trust | 0.92% | 1,454,497 SH | Sept. 11, 2026 | Daily |
| CALF · Pacer Funds Trust | 0.79% | 482,285 NS | July 31, 2026 | N-PORT |
| JOET · Virtus ETF Trust II | 0.76% | 30,936 NS | July 31, 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.73% | 60,076 NS | July 31, 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.72% | 14,556 SH | Oct. 23, 2026 | Daily |
| AFMC · First Trust Exchange-Traded Fund VI… | 0.71% | 23,122 NS | Aug. 31, 2026 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0.44% | 77,415 NS | July 31, 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0.44% | 24,133 NS | July 31, 2026 | N-PORT |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0.36% | 26,512 SH | Oct. 23, 2026 | Daily |
| IVOG · VANGUARD ADMIRAL FUNDS | 0.33% | 108,709 SH | Aug. 19, 2026 | Daily |
| PTMC · Pacer Funds Trust | 0.33% | 21,272 NS | July 31, 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0.32% | 436,803 NS | July 31, 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0.30% | 2,559,860 SH | Aug. 19, 2026 | Daily |
| IVOO · VANGUARD ADMIRAL FUNDS | 0.30% | 312,378 SH | Aug. 19, 2026 | Daily |
| BKMC · BNY Mellon ETF Trust | 0.28% | 29,895 NS | July 31, 2026 | N-PORT |
| IVOV · VANGUARD ADMIRAL FUNDS | 0.27% | 71,381 SH | Aug. 19, 2026 | Daily |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0.25% | 84,704 NS | July 31, 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0.25% | 2,838 NS | July 31, 2026 | N-PORT |
| PWS · Pacer Funds Trust | 0.20% | 821 NS | July 31, 2026 | N-PORT |
| IYH · iShares Trust | 0.20% | 111,984 SH | Sept. 11, 2026 | Daily |
| SMMD · iShares Trust | 0.17% | 102,244 SH | Sept. 11, 2026 | Daily |
| FNY · First Trust Exchange-Traded AlphaDE… | 0.17% | 16,041 NS | July 31, 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0.16% | 19,998 SH | Aug. 19, 2026 | Daily |
| DFAS · Dimensional ETF Trust | 0.16% | 401,829 NS | July 31, 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.15% | 84,531 NS | July 31, 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.15% | 534,462 SH | Aug. 19, 2026 | Daily |
| ISCG · iShares Trust | 0.15% | 21,366 SH | Sept. 11, 2026 | Daily |
| DEUS · DBX ETF Trust | 0.14% | 6,578 NS | Aug. 31, 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0.14% | 20,990 SH | Aug. 19, 2026 | Daily |
| ESML · iShares Trust | 0.13% | 56,252 SH | Sept. 11, 2026 | Daily |
| VB · VANGUARD INDEX FUNDS | 0.13% | 4,433,137 SH | Aug. 19, 2026 | Daily |
| IWS · iShares Trust | 0.12% | 286,469 SH | Sept. 11, 2026 | Daily |
| RWK · Invesco Exchange-Traded Fund Trust … | 0.12% | 28,178 SH | Oct. 23, 2026 | Daily |
| VXF · VANGUARD INDEX FUNDS | 0.12% | 2,217,617 SH | Aug. 19, 2026 | Daily |
| WSML · iShares Trust | 0.11% | 11,104 SH | Sept. 11, 2026 | Daily |
| FYEE · Fidelity Greenwood Street Trust | 0.11% | 3,901 NS | July 31, 2026 | N-PORT |
| PEXL · Pacer Funds Trust | 0.09% | 797 NS | July 31, 2026 | N-PORT |
| IWR · iShares Trust | 0.09% | 787,222 SH | Sept. 11, 2026 | Daily |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.08% | 11,498 SH | Oct. 23, 2026 | Daily |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.08% | 18,000 NS | July 31, 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.06% | 5,934 NS | July 31, 2026 | N-PORT |
| DFAT · Dimensional ETF Trust | 0.06% | 143,957 NS | July 31, 2026 | N-PORT |
| FBUF · Fidelity Greenwood Street Trust | 0.05% | 212 NS | July 31, 2026 | N-PORT |
| QARP · DBX ETF Trust | 0.05% | 614 NS | Aug. 31, 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.05% | 4,814 NS | July 31, 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.05% | 18,819 NS | July 31, 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.05% | 40,633 SH | Oct. 23, 2026 | Daily |
| DFAC · Dimensional ETF Trust | 0.04% | 347,063 NS | July 31, 2026 | N-PORT |
| MNZL · EA Series Trust | 0.04% | 168 NS | July 31, 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.03% | 19,135 NS | July 31, 2026 | N-PORT |
| IWD · iShares Trust | 0.03% | 425,477 SH | Sept. 11, 2026 | Daily |
| DSI · iShares Trust | 0.03% | 27,701 SH | Sept. 11, 2026 | Daily |
| REVS · Columbia ETF Trust I | 0.03% | 1,740 NS | July 31, 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.03% | 115,700 SH | Aug. 19, 2026 | Daily |
| DFUV · Dimensional ETF Trust | 0.03% | 74,321 NS | July 31, 2026 | N-PORT |
| TILT · FlexShares Trust | 0.03% | 9,322 NS | July 31, 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.03% | 45,169 SH | Oct. 23, 2026 | Daily |
| FHEQ · Fidelity Greenwood Street Trust | 0.02% | 3,375 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.02% | 44,514 NS | July 31, 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.02% | 6,143,206 SH | Aug. 19, 2026 | Daily |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.02% | 31,861 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.02% | 16,031 SH | Aug. 19, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.02% | 43,345 SH | Aug. 19, 2026 | Daily |
| IUSG · iShares Trust | 0.02% | 97,914 SH | Sept. 11, 2026 | Daily |
| IWB · iShares Trust | 0.02% | 130,403 SH | Sept. 11, 2026 | Daily |
| IYY · iShares Trust | 0.02% | 8,059 SH | Sept. 11, 2026 | Daily |
| ITOT · iShares Trust | 0.02% | 253,576 SH | Sept. 11, 2026 | Daily |
| IUSV · iShares Trust | 0.02% | 71,403 SH | Sept. 11, 2026 | Daily |
| RECS · Columbia ETF Trust I | 0.02% | 16,398 NS | July 31, 2026 | N-PORT |
| IWV · iShares Trust | 0.02% | 51,240 SH | Sept. 11, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.02% | 53,858 NS | July 31, 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 169,270 SH | Aug. 19, 2026 | Daily |
| DFLV · Dimensional ETF Trust | 0.00% | 1,028 NS | July 31, 2026 | N-PORT |
| IJH · iShares Trust | · | 6,782,201 SH | Sept. 11, 2026 | Daily |
| IJK · iShares Trust | · | 638,802 SH | Sept. 11, 2026 | Daily |
| IJJ · iShares Trust | · | 423,789 SH | Aug. 21, 2026 | Daily |
| XJH · iShares Trust | · | 26,404 SH | Sept. 8, 2026 | Daily |
| ISCB · iShares Trust | · | 8,699 SH | Sept. 11, 2026 | Daily |
| ISCV · iShares Trust | · | 27,848 SH | Sept. 11, 2026 | Daily |
| SMMV · iShares Trust | · | 29,688 SH | Aug. 19, 2026 | Daily |
BMRN Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
27 analysts · 2026-10-24Mean target $91.56 +64.2%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | · |
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | · |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | · |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | · |
| SMMT | $13.56B | -12.1 | · | · | -235.1% | · |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | · |
| PCVX | $6.05B | -8.2 | · | · | -26.6% | · |
| KYMR | $6.33B | -21.1 | -16.7% | -794.0% | -24.4% | · |
| KRYS | $7.20B | 36.0 | 33.9% | 52.6% | 18.1% | · |
Latest News Recent headlines mentioning this company
Trading Signals Recent buy/sell signals with entry price and risk/reward ratio
No open signal right now — no card is filled, and that's honest.
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.